Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

News In Brief

This article was originally published in The Gray Sheet

Executive Summary

Welch Allyn restructuring to cut jobs by 10% over three years. Neurovision v. NuVasive update. CMS opens coverage analysis on PET for solid tumors. More news briefs.

You may also be interested in...



Reimbursement In Brief

CMS issues proposed decision memo for PET for solid tumors and sends letter to Smith & Nephew clarifying G codes for negative pressure wound therapies. More reimbursement news.

Blues’ TEC Delivers Mostly Negative Assessments For Three Technologies

The Blue Cross Blue Shield Technology Evaluation Center considered balloon ostial dilation for the treatment for chronic rhinosinusitis; multianalyte testing for evaluation of adnexal masses; and nucleic acid sequencing-based testing of maternal plasma for fetal aneuploidy.

CMS Urged To Lift All Evidence-Development Restrictions On PET For Solid Tumors

Move to lift coverage-with-evidence-development restrictions is widely supported by industry, medical specialty societies and clinicians.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT031567

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel